相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study
Angelo Ruggiero et al.
DERMATOLOGIC THERAPY (2021)
Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review
Erica B. Lee et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
S. K. Mahil et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Guselkumab: Short-term effectiveness and safety in real clinical practice
Lourdes Fernandez-Freire et al.
DERMATOLOGIC THERAPY (2020)
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
E. del Alcazar et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study
A. -C. Fougerousse et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study
Raquel Rivera et al.
DERMATOLOGIC THERAPY (2020)
Real-life experience of guselkumab in patients with psoriasis
Igor Snast et al.
DERMATOLOGIC THERAPY (2020)
Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
Marco Galluzzo et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Long-term Single Center Experience in Treating Plaque Psoriasis With Guselkumab
Khalad Maliyar et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2020)
Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study
F. Benhadou et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
The pharmacological management of patients with comorbid psoriasis and obesity
Andrea Chiricozzi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
Alexander Egeberg et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy
G. Carretero et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1 Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis
Zhenling Yao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR
Kayleigh J. Mason et al.
JAMA DERMATOLOGY (2018)
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies
K. B. Gordon et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
The role of IL 23 in the treatment of psoriasis
Lluis Puig
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
New Insights in the Immunologic Basis of Psoriasis
Kristine E. Nograles et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2010)
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments An Observational Study
Annamaria Mazzotta et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2009)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
分享论文
